Loading stock data…
CHUGAI PHARMACEUTICAL CO (4519.T)
TSE¥7,574+206.00 (+2.80%)
Market ClosedLast close Jun 29
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Chugai Pharmaceutical Co., Ltd. in the Healthcare sector is trading at ¥7,574 with a market capitalization of $12.2T. Wall Street consensus targets ¥9,973 (15 analysts), implying a +31.7% move over the next 12 months. The stock is currently 29% below its 52-week high of ¥10,700, remaining 4.7% below its 200-day moving average. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +31.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (JPY) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | ¥1.26T↑ | ¥1.11T↓ | ¥1.17T↓ | ¥1.26T |
| Gross Profit | ¥783.48B↑ | ¥698.06B↓ | ¥831.20B↓ | ¥894.25B |
| Operating Income | ¥533.31B↑ | ¥439.17B↓ | ¥542.00B↓ | ¥598.83B |
| Net Income | ¥374.43B↑ | ¥325.47B↓ | ¥387.32B↓ | ¥434.01B |
Peer Comparison
JNJUNHPFE
Fundamentals
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Ava...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥12.22T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
28.15
Beta
Defensive asset. Lower volatility than the S&P 500.
0.55
Div Yield
Strong income play. Yield provides a meaningful total return floor.
175.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.71%
Volume
Today's trading volume
2.81M
Recent News
Major Asian Stock Markets Fall Amid Renewed Middle East Tensions
Major Asian stock markets closed lower Tuesday as new US military strikes on Iran dampened optimism
Sarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.
Sarepta Therapeutics is seeing lower demand for its flagship gene therapy, Elevidys, following a regulatory crackdown.
Earnings Season, Tehran Proposal Lift Asian Stock Markets
Asian stock markets largely gained ground Monday on strength in tech issues, and on media reports th
Is Chugai Pharmaceutical (TSE:4519) Still Attractively Priced After Its Strong Multi Year Run
Wondering if Chugai Pharmaceutical's share price still offers value after a strong multi year run? This article unpacks how the current price compares with several valuation checks. The stock last closed at ¥8,585, with a 3.2% decline over the past week and an 8.3% decline over the past month. It is still up 0.8% year to date and 34.6% over 1 year, and very large over 3 and 5 years. Recent coverage has focused on Chugai Pharmaceutical's position within the pharmaceuticals space in Japan and...
Rani Therapeutics Q4 Earnings Call Highlights
Rani Therapeutics (NASDAQ:RANI) executives highlighted what they described as a “transformational” 2025 during the company’s fourth-quarter and full-year earnings call, pointing to progress advancing its oral biologics delivery platform, the launch of a new clinical study, and a new strategic collab